PMID: 9635526Jul 11, 1998Paper

Relation between cellular doxorubicin binding ability to nuclear DNA and histologic response to preoperative chemotherapy in patients with osteosarcoma

Cancer
K KusuzakiY Hirasawa

Abstract

Although chemosensitivity to antiosteosarcoma agents is the most important prognostic factor in human osteosarcoma, none of the many chemosensitivity tests reported previously are reliable and clinically useful. In this study, the authors investigated the reliability and clinical availability of doxorubicin (Adriamycin; Adria Laboratories, Columbus, OH) binding assay (ABA) as a new chemosensitivity test for osteosarcoma. Doxorubicin (adriamycin [ADM]) binding ability (%AB) to nuclear DNA in isolated osteosarcoma cells was assessed by ABA in 14 patients with primary osteosarcoma who were treated with preoperative chemotherapy containing ADM and 6 patients with relapsed osteosarcoma after intensive chemotherapy. Histologic responses to preoperative chemotherapy were evaluated by percentage of tumor necrosis (%necrosis). Four of the 14 patients with primary osteosarcoma had %AB > 80% (97.3+/-3.7%) and demonstrated good histologic responses (>90% of %necrosis) to preoperative chemotherapy, whereas the remaining 10 patients had %AB < 80% (38.9+/-21.0%) and demonstrated poor responses. Patients with recurrent osteosarcoma that was clinically evaluated to be resistant to previous chemotherapy also had low %AB (34.2+/-28.3%). Because t...Continue Reading

References

Jun 15, 1978·The New England Journal of Medicine·S E SalmonT E Moon
Jul 1, 1977·Journal of the National Cancer Institute·N T Bech-HansenV Ling
Sep 15, 1992·Cancer·J L Biedler
Jan 1, 1992·Journal of Cancer Research and Clinical Oncology·N BaldiniM Campanacci
Jan 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P A MeyersG Rosen
Sep 1, 1992·Archives of Surgery·K A SkinnerG Rosen
Jan 1, 1985·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·K H Jones, J A Senft
Jan 1, 1983·Journal of Cancer Research and Clinical Oncology·G DellingM Salzer-Kuntschik
Nov 23, 1995·The New England Journal of Medicine·N BaldiniM Campanacci
Mar 1, 1995·Current Problems in Cancer·L J Goldstein
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·U SteinP Schmidt-Peter
Sep 1, 1994·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·M C GebhardtD S Springfield
Dec 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P PicciM Campanacci
Jan 1, 1993·Cancer Treatment and Research·S M BlaneyJ L Grem
May 1, 1993·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·J S WunderI L Andrulis
Mar 1, 1996·The Journal of Bone and Joint Surgery. American Volume·H TakeshitaH J Mankin
Mar 15, 1996·Cancer·E Brown, M Markman

❮ Previous
Next ❯

Citations

Jun 7, 2008·Clinical Orthopaedics and Related Research·Akira KawaiSetsuo Hirohashi
Jul 20, 2000·The Journal of Bone and Joint Surgery. American Volume·H TakeshitaY Hirasawa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.